前  言

現(xiàn)代醫(yī)學(xué)的發(fā)展將會獲得越來越復(fù)雜的數(shù)據(jù),，時間和空間上高度動態(tài)的系統(tǒng)數(shù)據(jù)將會對診斷,、治療和預(yù)測結(jié)果提供幫助。類器官有望成為治療各種胃腸道疾病的高價值系統(tǒng),，用于模擬免疫反應(yīng),、代謝機(jī)制,、腫瘤發(fā)生與發(fā)展、感染性消化道疾病等,。截止到2023年7月中旬,，全-球類器官的臨床研究超過170例，其中消化系統(tǒng)疾病的研究有70多例,。為了助力類器官的培養(yǎng)和研究,，義翹神州可提供自主研發(fā)的人源EGF、NOG,、RSPO1等重組細(xì)胞因子產(chǎn)品,。

01腸類器官研究進(jìn)展

腸類器官（Intestinal organoids）從人類腸道組織或干細(xì)胞中分離和培養(yǎng)構(gòu)建。通過在適當(dāng)?shù)呐囵B(yǎng)條件下處理這些細(xì)胞,，可以形成三維的腸道結(jié)構(gòu),。當(dāng)充分成熟時，人類腸道類器官會重現(xiàn)出芽的隱窩和絨毛結(jié)構(gòu)域,，分別含有增殖的ISC和祖細(xì)胞,，以及分化的腸上皮細(xì)胞、杯狀細(xì)胞和潘氏細(xì)胞,。

結(jié)腸類器官（colonic organoids）作為較早成功構(gòu)建的類器官模型之一,，在體外模擬結(jié)腸上皮的微環(huán)境,。目前有兩種較為成熟的,、基于成體細(xì)胞的結(jié)腸類器官模型，分別衍生于富含亮氨酸重復(fù)序列G蛋白偶聯(lián)受體5陽性（LGR5+）成體干細(xì)胞（ASC）和定向分化的誘導(dǎo)多能干細(xì)胞（iPSC）,。

腸道類器官被廣泛用于研究腸道發(fā)育,、功能和疾病。它們可以用于研究消化吸收,、腸道感染,、腸道炎癥、腸道腫瘤等疾病的發(fā)生機(jī)制,，并用于藥物篩選和個體化醫(yī)療研究,。腸道類器官在模擬人類腸道的復(fù)雜性和組織結(jié)構(gòu)方面具有一定的優(yōu)勢，因?yàn)樗鼈兏咏鎸?shí)的腸道環(huán)境,。

盡管腸道類器官在研究中具有重要的應(yīng)用價值,，但目前仍然存在著一些挑戰(zhàn)，如細(xì)胞培養(yǎng)的復(fù)雜性,、缺乏完整的腸道微生物群落等,。因此，腸道類器官仍在不斷發(fā)展和改進(jìn),，以更好地模擬和理解人類腸道的結(jié)構(gòu)和功能,，在腸道生理病理學(xué)基礎(chǔ)研究,、疾病建模、藥物篩選與開發(fā),、再生醫(yī)學(xué)等領(lǐng)域具有廣闊應(yīng)用前景,。

02細(xì)胞因子在腸類器官中的應(yīng)用

細(xì)胞因子作為類器官培養(yǎng)基的添加成分，對類器官培養(yǎng)起著重要作用,。比如,，EGF可以促進(jìn)腸上皮細(xì)胞增殖，Noggin使干細(xì)胞保持未分化的狀態(tài)并促進(jìn)增殖,，R-spondin-1具體促進(jìn)腸干細(xì)胞增殖的能力,。Li等人在進(jìn)行小鼠腸器官培養(yǎng)的時候，在培養(yǎng)基中加入50ng/mL EGF（貨號：50482-MNCH,，義翹神州）,、100ng/mL Noggin（貨號：50688-M02H，義翹神州）和500ng/mL R-spondin-1（貨號：11083-HNAS,，義翹神州）,。

?義翹神州細(xì)胞因子產(chǎn)品數(shù)據(jù)

Human RSPO1 Protein, Cat: 11083-HNAS

高純度：

≥ 95 % as determined by SDS-PAGE.  ≥95% as determined by SEC-HPLC.

高批間一致性

Induce activation of ?catenin response in a Topflash Luciferase assay using HEK293T human embryonic kidney cells.

Human Noggin Protein, Cat: 10267-HNAH

高純度：

≥95% as determined by SDS-PAGE. ≥95% as determined by SEC-HPLC.

高批間一致性

Inhibit BMP4-induced alkaline phosphatase production by MC3T3E1 mouse preosteoblast cells.

【參考文獻(xiàn)】

1. Taelman, J., Diaz, M., & Guiu, J. Human Intestinal Organoids: Promise and Challenge. Frontiers in cell and developmental biology, 2022. doi.org/10.3389/fcell.2022.854740

2. Kakni, P., et al. PSC-derived intestinal organoids with apical-out orientation as a tool to study nutrient uptake, drug absorption and metabolism. Frontiers in molecular biosciences, 2023. doi.org/10.3389/fmolb.2023.1102209

3. Rubert, J., et al. Intestinal Organoids: A Tool for Modelling Diet-Microbiome-Host Interactions. Trends in endocrinology and metabolism: TEM, 2022. doi.org/10.1016/j.tem.2020.02.004

4. Günther, C., et al. Organoids in gastrointestinal diseases: from experimental models to clinical translation. Gut, 2022. doi.org/10.1136/gutjnl-2021-326560

5. Wang, Q., et al. Applications of human organoids in the personalized treatment for digestive diseases. Signal transduction and targeted therapy, 2022. doi.org/10.1038/s41392-022-01194-6

6. Abud, H. E., et al. Source and Impact of the EGF Family of Ligands on Intestinal Stem Cells. Frontiers in cell and developmental biology, 2021. doi.org/10.3389/fcell.2021.685665

7. Krause, C., Guzman, A., & Knaus, P. Noggin. The international journal of biochemistry & cell biology, 2011. 

doi.org/10.1016/j.biocel.2011.01.007

8. Li, Y., et al. Bach2 Deficiency Promotes Intestinal Epithelial Regeneration by Accelerating DNA Repair in Intestinal Stem Cells. Stem cell reports, 2021. doi.org/10.1016/j.stemcr.2020.12.005

9. Chen, L., et al. Molecular Biomarker of Drug Resistance Developed From Patient-Derived Organoids Predicts Survival of Colorectal Cancer Patients. Frontiers in oncology, 2022. doi.org/10.3389/fonc.2022.855674

10. Tang, M., et al. Evaluation of B7-H3 Targeted Immunotherapy in a 3D Organoid Model of Craniopharyngioma. Biomolecules, 2022. doi.org/10.3390/biom12121744

11. Ruan, D., et al. Human early syncytiotrophoblasts are highly susceptible to SARS-CoV-2 infection. Cell reports. Medicine, 2022. doi.org/10.1016/j.xcrm.2022.100849